Literature DB >> 18827603

Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.

Junichi Okamoto1, Iwao Mikami, Yuichi Tominaga, Kristopher M Kuchenbecker, Yu-Ching Lin, Dawn T Bravo, Genevieve Clement, Adam Yagui-Beltran, M Roshni Ray, Kiyoshi Koizumi, Biao He, David M Jablons.   

Abstract

INTRODUCTION: Heat shock protein 90 (Hsp90) is an abundant molecular chaperone that mediates the maturation and stability of a variety of proteins associated with the promotion of cell growth and survival. Inhibition of Hsp90 function leads to proteasomal degradation of its mis-folded client proteins. Recently, Hsp90 has emerged as being of prime importance to the growth and survival of cancer cells and its inhibitors have already been used in phase I and II clinical trials.
METHODS: We investigated how 17-allylamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is implicated in human malignant pleural mesothelioma (MM).
RESULTS: We found that 17-AAG led to significant G1 or G2/M cell cycle arrest, inhibition of cell proliferation, and decrease of AKT, AKT1, and survivin expression in all human malignant pleural mesothelioma cell lines examined. We also observed significant apoptosis induction in all MM cell lines treated with 17-AAG. Furthermore, 17-AAG induced apoptosis in freshly cultured primary MM cells and caused signaling changes identical to those in 17-AAG treated MM cell lines.
CONCLUSION: These results suggest that Hsp90 is strongly associated with the growth and survival of MM and that inhibition of Hsp90 may have therapeutic potential in the treatment of MM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18827603      PMCID: PMC2656438          DOI: 10.1097/JTO.0b013e3181839693

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  50 in total

1.  Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.

Authors:  P N Münster; M Srethapakdi; M M Moasser; N Rosen
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

2.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

Review 3.  Contemporary management of malignant pleural mesothelioma.

Authors:  E G Butchart
Journal:  Oncologist       Date:  1999

4.  Mesothelioma clinical presentation.

Authors:  R Bueno
Journal:  Chest       Date:  1999-12       Impact factor: 9.410

5.  Overexpression of Hp95 induces G1 phase arrest in confluent HeLa cells.

Authors:  Y Wu; S Pan; S Che; G He; M Nelman-Gonzalez; M M Weil; J Kuang
Journal:  Differentiation       Date:  2001-06       Impact factor: 3.880

6.  p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.

Authors:  C T Yang; L You; K Uematsu; C C Yeh; F McCormick; D M Jablons
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

7.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

Authors:  Andrea D Basso; David B Solit; Pamela N Munster; Neal Rosen
Journal:  Oncogene       Date:  2002-02-14       Impact factor: 9.867

8.  Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Authors:  S Modi; A Kubo; H Oie; A B Coxon; A Rehmatulla; F J Kaye
Journal:  Oncogene       Date:  2000-09-21       Impact factor: 9.867

Review 9.  New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.

Authors:  Anna K Nowak; Richard A Lake; Hedy Lee Kindler; Bruce W S Robinson
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

Review 10.  The protein kinase B/Akt signalling pathway in human malignancy.

Authors:  Karleen M Nicholson; Neil G Anderson
Journal:  Cell Signal       Date:  2002-05       Impact factor: 4.315

View more
  25 in total

1.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

Review 2.  Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

Authors:  Roberto E Favoni; Antonio Daga; Paolo Malatesta; Tullio Florio
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Elevated levels of ribosomal proteins eL36 and eL42 control expression of Hsp90 in rhabdomyosarcoma.

Authors:  Sarah Shaikho; Christine C Dobson; Thet Naing; Bahram Samanfar; Houman Moteshareie; Maryam Hajikarimloo; Ashkan Golshani; Martin Holcik
Journal:  Translation (Austin)       Date:  2016-10-04

4.  BioPlex Display: An Interactive Suite for Large-Scale AP-MS Protein-Protein Interaction Data.

Authors:  Devin K Schweppe; Edward L Huttlin; J Wade Harper; Steven P Gygi
Journal:  J Proteome Res       Date:  2017-10-31       Impact factor: 4.466

5.  17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.

Authors:  Panagiotis K Karkoulis; Dimitrios J Stravopodis; Lukas H Margaritis; Gerassimos E Voutsinas
Journal:  BMC Cancer       Date:  2010-09-09       Impact factor: 4.430

6.  Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.

Authors:  Go Watanabe; Kevin E Behrns; Jae-Sung Kim; Robin D Kim
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-12       Impact factor: 3.333

Review 7.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

8.  A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.

Authors:  Jenette Creaney; Ian M Dick; Justine S Leon; Bruce W S Robinson
Journal:  Cancer Genomics Proteomics       Date:  2017 Mar-Apr       Impact factor: 4.069

9.  17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.

Authors:  Panagiotis K Karkoulis; Dimitrios J Stravopodis; Gerassimos E Voutsinas
Journal:  Tumour Biol       Date:  2015-12-11

Review 10.  The role of protein synthesis in cell cycling and cancer.

Authors:  Shai White-Gilbertson; David T Kurtz; Christina Voelkel-Johnson
Journal:  Mol Oncol       Date:  2009-06-11       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.